The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients With KRAS Wild-Type Unresectable Colorectal Liver-Limited Metastases
Open accessAbstract
Purpose: To assess the effects of cetuximab plus chemotherapy as first-line treatment for unresectable colorectal liver metastases (CLMs). Patients and Methods: After resection of their primary tumors, patients with KRAS wild-type synchronous nonresectable liver-limited metastases from colorectal cancer were randomly assigned to receive chemotherapy (FOLFIRI [fluorouracil, leucovorin, and irinotecan] or mFOLFOX6 [modified fluorouracil, leucovorin, and oxaliplatin]) plus cetuximab (arm A) or chemotherapy alone (arm B). The primary end point was the rate of patients converted to resection for liver metastases. Secondary end points included tumor response and survival. Results: The intent-to-treat population comprised 138 patients; 70 patients were randomly assigned to arm A and 68 to arm B. After a median of 25.0 months of follow-up, the 3-year overall survival (OS) rate and median survival time (MST) for all patients were 30% and 24.4 months, respectively. The R0 resection rates for liver metastases were 25.7% (18 of 70 patients) in arm A and 7.4% (five of 68 patients) in arm B, which were significantly different (P < .01). Patients in arm A had improved objective response rates (57.1% v 29.4%; P < .01), increased 3-year OS rate (41% v 18%; P = .013) and prolonged MST (30.9 v 21.0 months; P = .013) compared with those in arm B. In addition, in arm A, patients who had resection of liver metastases had a significantly improved MST (46.4 v 25.7 months; P < .01) compared with those who did not undergo surgery. Conclusion: For patients with initially unresectable KRAS wild-type CLMs, cetuximab combined with chemotherapy improved the resectability of liver metastases and improved response rates and survival compared with chemotherapy alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Abdalla, E. K., Vauthey, J.-N., Ellis, L. M., Ellis, V., Pollock, R., Broglio, K. R., Hess, K., & Curley, S. A. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000128305.90650.71 · Cited by 1,750
Nordlinger, B., Guiguet, M., Vaillant, J.-C., Balladur, P., Boudjema, K., Bachellier, P., Jaeck, D., & Association Française de Chirurgie (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1254::aid-cncr5>3.0.co;2-i · Cited by 1,722
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Trends in Long-Term Survival Following Liver Resection for Hepatic Colorectal Metastases
Choti, M. A., Sitzmann, J. V., Tiburi, M. F., Sumetchotimetha, W., Rangsin, R., Schulick, R. D., Lillemoe, K. D., Yeo, C. J., & Cameron, J. L. (2002) · Annals of Surgery · doi:10.1097/00000658-200206000-00002 · Cited by 1,454
Lièvre, A., Bachet, J.-B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,444
Folprecht, G., Gruenberger, T., Bechstein, W. O., Raab, H.-R., Lordick, F., Hartmann, J. T., Lang, H., Frilling, A., Stoehlmacher, J., Weitz, J., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70330-4 · Cited by 963
Maughan, T. S., Adams, R. A., Smith, C. G., Meade, A. M., Seymour, M. T., Wilson, R. H., Idziaszczyk, S., Harris, R., Fisher, D., Kenny, S. L., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60613-2 · Cited by 960
Bokemeyer, C., Bondarenko, I., Hartmann, J. T., de Braud, F., Schuch, G., Zubel, A., Celik, I., Schlichting, M., & Koralewski, P. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq632 · Cited by 775
Factors influencing the natural history of colorectal liver metastases
Stangl, R., Altendorf-Hofmann, A., Charnley, R. M., & Scheele, J. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92529-1 · Cited by 722
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases
Van Cutsem, E., Nordlinger, B., Adam, R., Köhne, C.-H., Pozzo, C., Poston, G., Ychou, M., & Rougier, P. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.04.012 · Cited by 587
Tveit, K. M., Guren, T., Glimelius, B., Pfeiffer, P., Sorbye, H., Pyrhonen, S., Sigurdsson, F., Kure, E., Ikdahl, T., Skovlund, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0915 · Cited by 533
Resection of Hepatic Metastases from Colorectal Cancer Biologic Perspectives
STEELE, G., & RAVIKUMAR, T. S. (1989) · Annals of Surgery · doi:10.1097/00000658-198908000-00001 · Cited by 525
Expanding Criteria for Resectability of Colorectal Liver Metastases
Pawlik, T. M., Schulick, R. D., & Choti, M. A. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0142 · Cited by 449
Guidelines for resection of colorectal cancer liver metastases
Garden, O. J. (2006) · Gut · doi:10.1136/gut.2006.098053 · Cited by 417
Selection of Patients for Resection of Hepatic Colorectal Metastases: Expert Consensus Statement
Charnsangavej, C., Clary, B., Fong, Y., Grothey, A., Pawlik, T. M., & Choti, M. A. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9023-y · Cited by 354
The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer
Goldberg, R. M., Rothenberg, M. L., Van Cutsem, E., Benson, A. B., Blanke, C. D., Diasio, R. B., Grothey, A., Lenz, H.-J., Meropol, N. J., Ramanathan, R. K., et al. (2007) · The Oncologist · doi:10.1634/theoncologist.12-1-38 · Cited by 239
Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases
Adam, R. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg731 · Cited by 238
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741
Delaunoit, T., Alberts, S. R., Sargent, D. J., Green, E., Goldberg, R. M., Krook, J., Fuchs, C., Ramanathan, R. K., Williamson, S. K., Morton, R. F., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi092 · Cited by 167
Effect of specialist decision-making on treatment strategies for colorectal liver metastases
Jones, R. P., Vauthey, J.-N., Adam, R. A., Rees, M. R., Berry, D. C., Jackson, R., Grimes, N., Fenwick, S. W., Poston, G. J., & Malik, H. M. A. (2012) · British journal of surgery · doi:10.1002/bjs.8835 · Cited by 146
Tabernero, J. M., Ciardiello, F., Rivera, F., Rodríguez-Braun, E., Ramos, F. J., Martinelli, E., Vega-Villegas, M. E., Roselló, S., Liebscher, S., Kisker, O., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp549 · Cited by 99
Chemotherapy-Associated Hepatotoxicity: Do We Need to Be Concerned?
Choti, M. A. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0512-7 · Cited by 87
Bokemeyer, C., Köhne, C. H., Rougier, P. R., Stroh, C., Schlichting, M., & Cutsem, E. V. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3506 · Cited by 85
metastases, A.-E. A. F. L., Petrelli, F., & Barni, S. (2012) · International Journal of Colorectal Disease · doi:10.1007/s00384-012-1438-2 · Cited by 61
Cited by
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Arnold, D., Lueza, B., Douillard, J.-Y., Peeters, M., Lenz, H.-J., Venook, A., Heinemann, V., Van Cutsem, E., Pignon, J.-P., Tabernero, J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx175 · Cited by 838
Yoshino, T., Arnold, D., Taniguchi, H., Pentheroudakis, G., Yamazaki, K., Xu, R.-H., Kim, T. W., Ismail, F., Tan, I. B., Yeh, K.-H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx738 · Cited by 573
Metadata
- Authors
- Ye, L.-C., Liu, T.-S., Ren, L., Wei, Y., Zhu, D.-X., Zai, S.-Y., Ye, Q.-H., Yu, Y., Xu, B., Qin, X.-Y., & Xu, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-06-01
- Volume
- 31
- Issue
- 16
- Pages
- 1931-1938
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2123548341
- Cited by
- 394
- References
- 29
- FWCI
- 22.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.